See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Stock Markets
Social Media
Tariffs
UK Economy
Taxes
Soccer
Donald Trump
Education
Senate
Artificial Intelligence
Published • loading... • Updated

Two-Year Data From TRILUMINATE Pivotal Study Presented for Abbott’s TriClip TEER System - Cardiac Interventions Today

Summary by Cardiac Interventions Today
March 31, 2025—Abbott announced late-breaking data from its TRILUMINATE pivotal trial of the TriClip transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR). The company noted that TriClip is approved for use in more than 50 countries, including in the United States, Europe, and Canada. According to Abbott, the findings showed that the TriClip device provided substantial and sustained improvements in the severity of…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
Cardiac Interventions TodayCardiac Interventions Today

Two-Year Data From TRILUMINATE Pivotal Study Presented for Abbott’s TriClip TEER System - Cardiac Interventions Today

March 31, 2025—Abbott announced late-breaking data from its TRILUMINATE pivotal trial of the TriClip transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR). The company noted that TriClip is approved for use in more than 50 countries, including in the United States, Europe, and Canada. According to Abbott, the findings showed that the TriClip device provided substantial and sustained improvements in the severity of…

Read Full Article
ADKhabarADKhabar

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiologys Annual Scientific Session & Expo (ACC.25)

– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile – – Lorundrostat is a highly selective aldosterone synthase inhibitor that disrupts aldosterone biosynthesis rather than blocking the mineralocorticoid receptor – – Data from Advance-HTN […]

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ADKhabar broke the news in on Sunday, March 30, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

New Orleans

New Orleans

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal